I'm looking for a job. I exported this list from FewerJobs.com - a curated job board. Please: 1. Rank these jobs by fit for me, given my resume / skills. 2. Highlight the top 5 with a one-sentence rationale each. 3. Flag any concerns, including benefit values without source-backed evidence. 4. Suggest one or two filter changes I could make on FewerJobs to find more good matches. Filters I applied: - q: Revolution Medicines - quality_floor: default - match_401k_strict: true - parental_strict: true - non_birth_strict: true - pto_strict: true - include_older: false - apply_url_verified: false - page: 2 - per_page: 100 - sort: relevance Jobs (100 total): --- TITLE: Vice President, Analytical Development & Quality Control EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $294K-$367K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695261003 EXCERPT: Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline. --- TITLE: Senior Director, Country Manager, Switzerland EMPLOYER: Revolution Medicines LOCATION: Basel, Basel-Stadt, Switzerland (unspecified) SALARY: Not disclosed POSTED: 2026-04-29 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7720200003 EXCERPT: Senior Director, Country Manager, Switzerland Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Vice President, General Manager, Mid-Sized Markets of Europe, the Country Manager, Switzerland will lead the expansion efforts critical to maximizing the opportunity for Revolution Medicines (RevMed) innovation to help patients. In collaboration with the regional leadership team, the successful catalytic leader will develop and execute commercial and operational strategy to accelerate the engagement with key stakeholders and customers (government authorities, regulatory authorities, payer authorities, KOLs) in Switzerland as well as all necessary constituencies to support expansion into the European region - ensuring that reimbursement and access considerations are integrated in the existing and future clinical program design of the company portfolio / pipeline. The incumbent will be responsible for developing pre-launch and commercialization strategic plans for Switzerland and providing Swiss-specific input into lifecycle plans across the RevMed portfolio. This individual will have full accountability for the Switzerland P&L, all Switzerland operations --- TITLE: Senior Director, Medical Affairs, Italy EMPLOYER: Revolution Medicines LOCATION: Remote (Italy) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717894003 EXCERPT: Senior Director, Medical Affairs, Italy Remote (Italy) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, General Manager, Italy the Senior Director, Medical Affairs, Italy is the medical leader responsible for defining and executing the local medical strategy for oncology products. This role serves as the medical voice within the Italian Leadership Team, ensuring scientific excellence, compliant medical engagement, and strong alignment between global strategy and local patient, physician, and healthcare system needs. This leader will ensure that Italian medical considerations are embedded in the regional medical strategy and plans and will partner with the General Manager and crossfunctional teams, as well as the VP, Head of Europe Medical Affairs and their leadership team. The incumbent will contribute to building the Italian medical team and work closely with the Global and Regional Medical Affairs teams across Med Affairs functions. Responsibilities: - Act as the Medical Affairs lead for Italy, accountable for local medical strategy, execution, and impact --- TITLE: Executive Director, Portfolio Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2025-04-24 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=6530477003 EXCERPT: Executive Director, Portfolio Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are looking for a highly motivated individual with experience in portfolio management, decision analysis and a passion for developing solutions for complex problems to build out this cross-functional capability and help shape our portfolio strategy. This position will report to the SVP, Development Management and Program Leadership and will be based at our headquarters in Redwood City, CA. In this highly cross functional role, you will be expected to evolve the wider portfolio management capability within Revolution Medicines and closely collaborate with Portfolio Working Group, Disease Area Teams, Program Teams, Life Cycle Teams, Analytics and Insights, Finance, Commercial and many other relevant functions. You must be entrepreneurial, able to “roll up their sleeves” and thrive in a fast-paced, highly cross-functional environment. You are an exceptional strategic and critical thinker, have a passion for interpreting and analyzing complex data, and have strong interpersonal --- TITLE: Executive Director, Clinical Supply Chain EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695198003 EXCERPT: Executive Director, Clinical Supply Chain Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director, Clinical Supply Chain provides strategic leadership and operational oversight for end-to-end clinical supply chain activities across the organization. Strategic Leadership - Define and execute the global clinical supply chain strategy aligned with the company's clinical development pipeline and long-term business goals. - Establishes strategies and processes to ensure uninterrupted supply for Revolution Medicines portfolio across all phases of development. - Lead and serve as subject matter expert for clinical supply chain planning, risk management, and execution of clinical supply chain activities. - Build scalable processes and infrastructure to support early- through late-phase clinical programs. - Strategic Planning on comparator sourcing management to ensure timely, compliant and cost-effective product availability. - Effective management of clinical studies executed in conjunction with collaboration partners. - Identify and implement overall clinical supply chain best practices. Clinical Supply Operations - Oversee end-to-end clinical supply --- TITLE: Senior Director, Pipeline & Product Communications EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695609003 EXCERPT: Senior Director, Pipeline & Product Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Pipeline & Product Communications will lead the strategy, development, and execution of integrated communications across the company's pipeline and product candidate portfolio. This role is accountable for shaping how Revolution Medicines' pipeline and product narratives are understood by external stakeholders, including scientific and medical audiences, patients and advocates, media, and the broader healthcare ecosystem. Reporting to the Head of Communications, this leader will serve as a trusted strategic advisor to cross-functional partners across R&D, Medical Affairs, Regulatory, Commercial, Market Access, Patient Advocacy, Legal, and Investor Relations. The role requires deep expertise across the full product lifecycle, from early clinical development through regulatory milestones and launch readiness, and the ability to translate complex science into clear, differentiated, and credible narratives. This is a high-impact leadership role for a communications professional who thrives at the intersection of science, strategy, people --- TITLE: Associate Director, Clinical Operations EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7684894003 EXCERPT: Associate Director, Clinical Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional who has innate leadership and organizational skills, technical expertise in clinical oncology drug development in an industry setting, and experience in overseeing clinical trials. As an Associate Director, you will be responsible for the Contract Research Organization (CRO) oversight, execution, and management of Revolution Medicines (RevMed) clinical trials. Responsibilities: - Adhere to Clinical Standard Operating Procedures (SOP) and Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Global experience in end-to-end execution of different phases of clinical trials. - Accountable for study delivery goals. Oversee the successful management of all aspects of clinical trials within timelines and designated program budgets. - Guide assessment, selection, engagement, management, and oversight of appropriate vendors. - Responsible for making decisions that balance risk/benefit with clear understanding of impact on the study and project; takes --- TITLE: Associate Director, Biostatistics – Early Phase EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-23 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7712274003 EXCERPT: Associate Director, Biostatistics – Early Phase Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This position is to serve as a study level statistician for oncology studies, and to coordinate activities with other functional groups to ensure timely deliverables. - Represent biostatistics on study/project teams. - Provide statistical expertise for design, analysis and reporting of clinical studies. - Collaborate with various functions on study design and planning, protocol development, statistical methodology and analysis. - Develop statistical analysis plans and analysis specifications. - Collaborate with statistical programming to ensure that analysis is conducted per statistical plan and specifications. - Collaborate with data management and clinical operations to ensure robust CRF and database development and quality data collection. - Provide statistical input to regulatory interaction and response to health authority submissions. - Collaborate in publications, assist in data interpretation, and ensure consistency and accuracy in data presentation. - Contribute to the development of functional-level standards, SOPs, and --- TITLE: Senior Director, Executive & Enterprise Communications EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-05-01 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7613269003 EXCERPT: Senior Director, Executive & Enterprise Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Executive & Enterprise Communications will serve as a trusted communications advisor to the CEO and select senior leaders while leading enterprise internal communications across a growing global organization. This is a high-impact role for a communicator who can operate strategically and execute with excellence. Success in this position requires sound judgment, executive presence, strong writing skills, and the ability to move seamlessly between shaping a CEO keynote and building the communications infrastructure that keeps teams informed, aligned, and engaged. Reporting to the Head of Communications, this role partners closely with the Corporate Communications lead, the Associate Director of Internal Communications, and regional communications and HR partners globally. This is a rare opportunity to work directly with RevMed's executive leadership team, shaping executive voice, internal culture, and enterprise communications at a company rapidly building toward commercial stage. Key responsibilities --- TITLE: Associate Director, Clinical Development EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695416003 EXCERPT: Associate Director, Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical scientist to serve as Associate Director, Clinical Science in support of Revolution Medicines' late-stage clinical programs. In this role, you will independently lead defined clinical science workstreams within pivotal and supportive studies and support execution of the registrational clinical development strategy for assigned molecule(s) and indication(s). The Associate Director plays a critical role in ensuring high-quality clinical data review, protocol consistency, and submission-readiness for late-stage programs. This position operates with substantial autonomy within assigned scope and collaborates closely with more senior clinical science team members and the study Medical Director to ensure medically sound and regulatory-aligned execution. Furthermore: - Independently lead defined clinical science workstreams within pivotal and registration-enabling studies (e.g., endpoint strategy, data review oversight, CSR section ownership, data consistency initiatives). - Contribute substantially to protocol development, CRF design, ICF updates, and alignment of data standards --- TITLE: Director, CMC Regulatory, Europe EMPLOYER: Revolution Medicines LOCATION: Basel, Basel-Stadt, Switzerland (unspecified) SALARY: Not disclosed POSTED: 2026-04-20 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7708726003 EXCERPT: Director, CMC Regulatory, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As part of our expanding European organization, we seek a strategic and hands-on Director, CMC Regulatory, Europe who will be responsible for developing and executing regional CMC regulatory strategies to support early development, marketing authorizations, and lifecycle management across Europe. This role is responsible for ensuring successful interactions with the European Medicines Agency (EMA), national competent authorities (NCAs), and other regional regulatory bodies. It provides leadership across early- and late-stage CMC regulatory activities, including clinical trial applications, initial marketing authorization applications (MAA), post-approval variations, and lifecycle strategy. The position requires deep expertise in EU regulatory frameworks, strong cross-functional collaboration, and the ability to proactively identify and manage regulatory risks while supporting business objectives. Primary Responsibilities: - Provide CMC regulatory support for clinical trial applications and regulatory interactions, ensuring alignment with EU requirements and timelines. - Develop and lead execution of European CMC regulatory strategies to --- TITLE: Senior Manager, Regulatory Affairs EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695449003 EXCERPT: Senior Manager, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager of Regulatory Affairs will provide project teams with regulatory advice, manage and coordinate various Regulatory Affairs activities within and between departments, and obtain and maintain National Health Authority approvals for investigational products. The position may also undertake regulatory intelligence and research supporting company decision-making. - Manage planning, preparation, coordination, and submission of regulatory documents to global National Health Authorities. Such submissions may include Clinical, Preclinical, or CMC content. - Correspond and collaborate with RevMed colleagues and departments to achieve alignment. - Function as a Regulatory Affairs subject matter expert member of cross-functional teams, including study teams and submission teams. - Perform regulatory research to inform business strategy. Assess and communicate risks. - Assure that there are no significant interruptions to the business due to regulatory compliance issues. - Collaborates across the organization at all levels, across functional groups, and with --- TITLE: Senior Corporate Counsel, Contracts (Clinical Development) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$282K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695536003 EXCERPT: Senior Corporate Counsel, Contracts (Clinical Development) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Corporate Counsel, Contracts (Clinical Development) will support the Company's clinical research and development activities by drafting, negotiating, and advising on a broad range of clinical and research-related agreements. This role partners closely with Clinical Development, Clinical Operations, Biometrics, Medical Affairs, Procurement, and Legal and Compliance teams to enable efficient and compliant execution of clinical programs. The ideal candidate has strong experience with clinical trial agreements and related contracts in a biotech or pharmaceutical setting, excellent judgment, and the ability to manage multiple priorities in a fast-paced environment. Key responsibilities include: - Draft, review, and negotiate a wide range of clinical development agreements, including: - Clinical Trial Agreements (CTAs). - Site agreements and amendments. - CRO, SMO, and vendor agreements. - Consulting agreements for investigators and key opinion leaders. - Data sharing, biometrics, and lab services agreements. - Advise internal --- TITLE: Director, Global Insights EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7693938003 EXCERPT: Director, Global Insights Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Senior Director, Global Insights, the Director, Global Insights role requires strategic thinking and expertise to provide critical contributions to disease area strategy, life-cycle planning and product and portfolio decisions. The individual in this role will be responsible for conducting market research in a variety of geographies to help support the development and potential commercialization of the RevMed portfolio and will be an influential voice in developing asset strategy. The ideal candidate will have experience working on pipeline molecules in Oncology across multiple geographies, strong problem-solving skills, a strategic mindset, and will exhibit curiosity, flexibility, and be comfortable with ambiguity. This position would ideally be based at our headquarters in Redwood City, CA., however open to remote candidates who are willing to travel to our CA office on a regular basis. Responsibilities include: - Works cross functionally to develop and execute --- TITLE: Senior Director, Market Access, France EMPLOYER: Revolution Medicines LOCATION: Paris, France (unspecified) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717855003 EXCERPT: Senior Director, Market Access, France Paris, France Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Market Access is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities. This position will partner with commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches. Responsibilities: - Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the France healthcare system. - HTA & Pricing Filings: Lead preparation and submission of value dossiers, --- TITLE: Senior Manager, Compliance - Field Commercialization (West) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-30 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7648499003 EXCERPT: Senior Manager, Compliance - Field Commercialization (West) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Compliance - Field Commercialization is responsible for providing hands-on support to Commercial and Medical field teams during product commercialization and indication expansion. This role serves as a primary field-facing compliance partner, ensuring compliant execution of field activities while enabling business objectives. Reporting to the Senior Director, Compliance the Senior Manager will implement and continuously enhance a comprehensive field-facing compliance program, embedding compliance into daily field operations while supporting the company's growth as commercial stage oncology organization. Field Compliance Support - This role will support the Senior Director, Compliance in providing field-facing corporate compliance support for all Revolution Medicines (RevMed) field roles, including field Sales, field Marketing, Medical Science Liaisons, and field Reimbursement and Access teams. - This role will serve as primary compliance contact for questions related to field activities. - The Senior Manager will partner with --- TITLE: Senior Payroll Specialist EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $120K-$150K POSTED: 2026-05-06 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7726726003 EXCERPT: Senior Payroll Specialist Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a motivated individual to play a critical role in the payroll team. Reporting directly to the Associate Director, Payroll, this position requires a meticulous individual who thrives in a fast-paced environment and has experience in high-volume, deadline-driven payroll operations. This position will work closely with internal stakeholders and external vendors to drive impactful improvements within the Sr. Payroll Specialist area of focus. Key Responsibilities: - Perform accurate and timely semi-monthly payroll processing for US employees including special runs such as off-cycle processing using ADP Workforce Now. - Work with the HR team regarding payroll related items such as benefit deductions, leave-of-absences, onboarding of new employees, termination of existing employees, and data validation in ADP. - Serve as the primary point of contact for payroll-related inquiries and foster a collaborative and high-performance work environment with an open and two-way communication ambience. --- TITLE: Senior Director, Clinical Data Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-06-09 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7766570003 EXCERPT: Senior Director, Clinical Data Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials. Key responsibilities include leading and managing data management teams, establishing and enforcing data management policies and procedures, overseeing departmental budgets, collaborating with cross-functional teams and vendors, and ensuring data management processes meet regulatory standards. This role requires extensive experience in clinical data management, strong leadership and communication skills, expertise in clinical trial methodologies, and a deep understanding of regulatory requirements including submissions and data management systems. Required Skills, Experience and Education: - Define and implement the overall vision, strategy, and goals for the clinical data management department, including developing and enforcing departmental SOPs. - Lead, manage, and develop data management teams, handling resource planning, staff training, and performance reviews. --- TITLE: Associate Director, Regulatory Operations, Europe EMPLOYER: Revolution Medicines LOCATION: Basel, Basel-Stadt, Switzerland (unspecified) SALARY: Not disclosed POSTED: 2026-04-29 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7719967003 EXCERPT: Associate Director, Regulatory Operations, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Operations, Europe will play a key role in supporting the growing European Regulatory Affairs organization by leading the operational planning and execution of regulatory submissions across the region. This role partners closely with the European Regulatory Affairs team to operationalize regional regulatory strategies and ensure successful execution of regulatory submissions to health authorities across the EU, EEA, UK and Switzerland. Working cross-functionally with regulatory strategy, clinical, CMC, nonclinical, and quality teams, the Associate Director will drive submission planning, manage regulatory documentation, and coordinate cross-functional teams to deliver high-quality submissions in accordance with global and regional regulatory operations processes and systems. While primarily focused on the European region, this role operates within Global Regulatory Operations and may support regulatory submissions in other regions as business needs evolve. Primary Responsibilities: - Serve as the primary Regulatory Operations partner supporting the European Regulatory --- TITLE: Executive Director, Global Privacy EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $311K-$357K POSTED: 2026-05-05 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7725117003 EXCERPT: Executive Director, Global Privacy Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: RevMed is seeking an experienced privacy executive to support RevMed's business. The Executive Director, Global Privacy will lead the strategy, development, and execution of the company's Privacy Program, ensuring all activities are conducted ethically and in accordance with applicable laws, regulations, and industry codes. This attorney will be instrumental in shaping and sustaining a culture of integrity as the company advances and commercializes its oncology pipeline. The Executive Director, Global Privacy is a senior leader responsible for driving the organization's global privacy strategy, governance, and compliance framework. This role ensures that all business activities involving personal data are conducted ethically and in compliance with applicable international laws, regulations, and industry standards. Reporting to the Vice President, Compliance, this role serves as a key advisor to the General Counsel (GC) and other senior executives on global privacy, data protection, and responsible data use, while --- TITLE: Associate Director, Global Quality System & Compliance EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-29 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7719794003 EXCERPT: Associate Director, Global Quality System & Compliance Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Provide strategic and operational leadership to scale and globalize the Quality Management System (QMS), establishing a harmonized, flexible framework that supports international growth and regulatory compliance. - Lead oversight and expansion of core quality systems across global sites, including document control, GxP training, quality events, supplier management, audits, and batch release. - Partner with regional teams (including Japan, Europe & other global regions) to integrate local regulatory requirements into the global QMS while maintaining global consistency. - Establish and govern global quality procedures, including policies, SOPs, and standardized processes to ensure compliance and operational efficiency. - Ensure inspection readiness and lead support for global health authority inspections, regulatory submissions, and product launches. - Oversee global quality metrics, compliance monitoring, and management review processes; drive proactive identification, escalation, and mitigation of quality risks. - Provide governance for electronic quality and --- TITLE: Associate Director, CMC Regulatory EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-05-18 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7736323003 EXCERPT: Associate Director, CMC Regulatory Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed's pipeline compounds/products. This role involves coordinating and preparing CMC sections of regulatory submissions to support RevMed's global clinical trials, market applications and post approval changes. The ideal candidate should have a strong understanding of global regulatory requirements during different phases of development, and be able to provide regulatory guidance to the CMC teams accordingly. Responsibilities: - Develop, lead, and implement global CMC regulatory strategies to support the clinical development, registration, and post-marketing activities. - Lead the preparation and maintenance of the CMC / quality sections for regulatory submissions including initial submission of IND, IMPD/CTA, NDA, MAA and amendments to Health Authorities (HAs), and preparation of responses to --- TITLE: Associate Director, Regulatory Operations - Systems EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7693857003 EXCERPT: Associate Director, Regulatory Operations - Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Operations Systems role contributes to the development, implementation, and governance of regulatory operation systems. This role serves as the subject matter expert for RIM, regulatory operation infrastructure, driving submission excellence, process optimization, compliance readiness, and system innovation across the Regulatory organization in line with global regulatory expectations and Global Regulatory Affairs (GRA) technology roadmap. Core responsibilities include driving RIM and other RO systems projects across the business, guiding the team through challenges and aligning with the overall business strategy and business development. - Support and lead activities related to regulatory operation infrastructure and system maintenance, guiding the team through challenges and aligning with the overall business strategy. - Contributes to the development, implementation, and governance of RIM and publishing system. - Provides independent leadership and direction on regulatory specifications for RIM systems, working closely with cross-functional teams --- TITLE: Global Development Lead (GDL), Clinical Development EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $369K-$424K POSTED: 2026-05-15 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7720354003 EXCERPT: Global Development Lead (GDL), Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines' most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning. The GDL functions as the single point of clinical accountability for the assigned program, setting direction, driving alignment across functions, and representing the program at internal governance bodies and externally with investigators, key opinion leaders, and global health authorities. This position sits at the Executive Director level within Clinical Development and carries program-level accountability and authority typically associated with the most senior clinical leaders in the organization. In addition to program ownership, the GDL serves as a senior clinical advisor to development leadership, contributing perspective to cross-program and enterprise-level --- TITLE: Regional Insights and Engagement Director, Northeast EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $231K-$254K POSTED: 2026-05-20 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7732653003 EXCERPT: Regional Insights and Engagement Director, Northeast Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Regional Insights and Engagement Director, Northeast is a field-based position focused on working closely with Lung Cancer Key Opinion Leaders (KOLs) at select institutions and accounts within the defined geography. This person is a RevMed clinical and product expert for Key Opinion Leaders and ensures that cross-functional resources are made available as appropriate. In this role, you will be a member of the commercial development team, and you will work closely with marketing, medical affairs, field sales, insights and analytics and other cross functional colleagues. You will help inform brand strategy, develop and execute KOL tactics and you will be evaluated in conjunction with individual performance and brand KPIs. This role will cover major academic institutions, accounts, and the Lung Key Opinion Leaders located in the Northeast. Essential Duties: - Designs, executes, and implements significant national strategic marketing deliverables. - --- TITLE: Director, Analytical Development EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-05-13 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7732695003 EXCERPT: Director, Analytical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Provide strategic and organizational leadership for analytical development activities supporting small molecule API and drug product development, including oversight of phase appropriate control strategies, specification setting, analytical lifecycle management, and overall CMC analytical strategy. - Lead and oversee analytical development execution across internal and external teams to support the development, characterization, and manufacturing of API and drug product, while actively contributing to cross functional PDM project teams. - Provide strategic guidance and oversight for regulatory submission activities, including authoring and review Quality sections of regulatory submissions, and leading responses to regulatory queries. - Establish and drive analytical strategies, technology selection, and operational execution through effective management of CDMOs, CROs, and contract laboratories, with accountability for quality, timelines, risk management, and delivery. - Provide leadership oversight for preparation, review, and approval of analytical protocols, reports, specifications, investigations, and technical documentation to ensure scientific excellence, --- TITLE: Director, Global Value, Access & Pricing – CRC EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $201K-$251K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7694070003 EXCERPT: Director, Global Value, Access & Pricing – CRC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Value, Access & Pricing - CRC is responsible for developing and driving global access and pricing strategies for Revolution Medicines' CRC assets to enable timely, sustainable patient access across key markets. This role ensures payer and HTA requirements are embedded into clinical development, indication sequencing, and launch planning from early-stage development through commercialization. The Director serves as the global access lead on cross-functional asset teams and partners closely with HEOR, Clinical Development, Regulatory, Commercial, Finance, and Regional Market Access to align global strategy with regional execution. Key responsibilities: - Lead development of global pricing and market access strategies for CRC assets, including launch sequencing, reference pricing considerations, and price corridor management across priority markets. - Identify payer-relevant evidence requirements and partner with HEOR to align evidence generation plans with global reimbursement needs. - Assess CRC competitive dynamics, including --- TITLE: Senior Clinical Data Manager EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $138K-$172K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695503003 EXCERPT: Senior Clinical Data Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Opportunity: The Senior Clinical Data Manager is responsible for all aspects of the data management process from the development of project documentation, system set-up, User Acceptance Testing (UAT), routine data review through database lock of clinical trials. The Sr/CDM has a broad, fundamental knowledge of the data management process and can plan, manage and coordinate all Data Management activities for assigned study(ies) with minimal guidance. This person may have project level oversight of junior data managers and/or Clinical Data Associates (CDAs). The core duties and responsibilities of the Sr/CDM are delineated below. Specifically, you will be responsible for: - Represents data management in study team meetings, able to facilitate and provide data management updates and/or input when appropriate. - Manages data management timelines to coordinate and synchronize deliverables with the overall study timelines. - Generates and/or reviews/approves study documents (e.g. Data Management Plans, Case Report --- TITLE: Senior Manager, Sales Operations & Analytics EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $150K-$189K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7697166003 EXCERPT: Senior Manager, Sales Operations & Analytics Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Sales Operations & Analytics, reporting to the Senior Director, Sales Operations & Analytics, plays a key role in enabling US Commercial field teams to execute with clarity and impact. This leader partners cross-functionally to translate strategy into scalable processes, actionable insights, and effective, pragmatic, high-impact tools that drive alignment and position the field for success. This individual will support seamless, coordinated commercial field enablement through: Field Operations & Governance - Translate commercial strategy into clear, compliant, and executable field processes. - Lead operating cadence, governance forums, and communications to drive alignment and accountability. - Maintain SOPs and field standards to ensure consistent execution. Sales Systems, Territory & Data - Oversee operations and infrastructure of core field enablement systems including CRM, alignment management, roster management, and sales crediting. - Ensure data integrity, system adoption, territory accuracy, and reporting reliability. - Lead --- TITLE: Director, Medical Information, Japan EMPLOYER: Revolution Medicines LOCATION: Remote (Japan) (remote) SALARY: Not disclosed POSTED: 2026-05-15 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7687157003 EXCERPT: Director, Medical Information, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated and experienced professional to join our team as a Director of Medical Information supporting Japan. This role focuses on ensuring the delivery of timely, accurate, and evidence-based responses to healthcare professionals (HCPs), patients, and caregivers. As a key member of the Medical Affairs team, you will oversee the creation and management of medical information content, provide scientific and operational oversight of Japan medical information call center team, contribute to medical booth asset creation, and contribute to dossier development and review. This role will also provide Medical Information support at scientific congresses and collaborate cross-functionally to support both pipeline assets and companion diagonstics. The ideal candidate is a skilled communicator with a strong scientific background and can manage projects in a dynamic environment. This role will report to the Head of Medical Information within the Global Medical Excellence team. Key Responsibilities: - --- TITLE: Director, Program Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-04-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7710416003 EXCERPT: Director, Program Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is an exciting, high-profile, and highly visible Program Management opportunity to advance a first-in-Class RAS(ON) Inhibitor through clinical development. The ideal candidate is a very proficient and self-motivated program manager with a solid understanding of drug development. The Director, Program Management partners with the Project Team Leader (PTL) on the translation of program strategy into an efficient execution plan; they understand the competitive landscape and clinical context to manage the cross-functional dependencies and connections. They understand the breadth of cross-functional activities and can foster productive collaborations to ensure successful execution. Overall, the Director, Program Management makes things happen via productive collaborations in an organization that is rapidly developing its capabilities and infrastructure. They not only care about the outcomes but how we get there. The successful candidate will draw upon their experience to: - Partner with the PTL in defining program strategy, stakeholder --- TITLE: Senior Scientist I, Computational Chemistry EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $149K-$186K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695451003 EXCERPT: Senior Scientist I, Computational Chemistry Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated Senior Scientist I to join our dynamic Computational Chemistry team.This position offers an exciting opportunity to drive drug discovery through cutting-edge computational methods, working at the intersection of structural biology, medicinal chemistry, biology, and data science to accelerate the development of transformative therapeutics for patients. As a key contributor in our Computational Chemistry team, you will: - Partner with multidisciplinary, collaborative teams in Discovery Sciences to design, optimize, and accelerate the discovery of novel drug candidates using structure-based computational methods. - Analyze structure-activity relationships (SAR) and make data-driven decisions by systematically following existing SAR trends to guide compound prioritization and design strategies for Ro5 and bRo5 molecules. - Partner closely with Medicinal Chemists to prioritize compound designs both independently and collaboratively, effectively communicating scientific rationale and recommendations to diverse interdisciplinary teams. - Design and implement virtual screening --- TITLE: Associate Director, Medical Analytics and Exploratory Data Science EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7693791003 EXCERPT: Associate Director, Medical Analytics and Exploratory Data Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly capable Associate Director of Biostatistics to join our Medical Analytics and Exploratory Data Science Biostatistics group within our Biostatistics organization. This role will play a critical part in the design, analysis, and interpretation of exploratory data analyses, scientific publications, real-world evidence (RWE), post-marketing research, and health economics and outcomes research (HEOR) studies. The successful candidate will serve as a key statistical contributor and emerging leader, partnering closely with cross-functional teams to deliver high-quality, data-driven insights that support scientific understanding and evidence generation. - Lead statistical design, analysis, and interpretation for exploratory data analyses using existing clinical trial data, real world data studies, post-marketing research, and HEOR projects. - Partner closely with other subfunctions within quantitative sciences and with cross-functional teams, including clinical development, medical affairs, safety, statistical programming, regulatory affairs and commercial, to execute --- TITLE: Senior Director & Therapeutic Area Head, Regulatory Affairs EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695273003 EXCERPT: Senior Director & Therapeutic Area Head, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Provide management and leadership of one or more therapeutic areas for late-stage oncology programs. - Oversee the development of global regulatory therapeutic area and product strategies to drive product development, global registration, , and effective regulatory agency interactions. - Provide regulatory expertise and guidance to therapeutic area commercialization teams and other governance bodies. - Foster the career development of staff within the therapeutic area and contribute to departmental leadership activities. - Ensure alignment and consistency across programs within a therapeutic area based on regulatory intel, research, and competitive landscape. Primary Responsibilities: - Direct the development of global regulatory strategy from registrational studies to marketing application across one or more therapeutic areas. - Lead and mentor GRLs/Study Leads in the development of global regulatory strategies, in partnership with regional regulatory leads, including precedence, risk management and contingency planning. - --- TITLE: Senior Manager, Business Analysis and Project Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-14 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695694003 EXCERPT: Senior Manager, Business Analysis and Project Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Business Analysis & Project Management is a strategic leadership role within the Information Sciences organization, responsible for driving enterprise technology initiatives that support pharmaceutical research, development, manufacturing, quality, and commercial operations. This role requires creation of business and Sciences requirements leading to delivery of complex, cross-functional projects while maintaining compliance with regulatory and validation requirements. The role partners closely with business and IS leadership to translate business strategies into scalable, compliant technology solutions, while ensuring projects are delivered on time, within scope, and within budget. Key Responsibilities: Strategic Leadership & Governance - Develop and execute the Business Analysis and Project Management strategy aligned with enterprise IS and business objectives. - Establish and enforce standardized methodologies, templates, tools, and best practices (Agile, Waterfall, Hybrid). - Provide portfolio-level oversight, prioritization, and delivery governance for IS initiatives. - Serve as --- TITLE: Associate Principal Statistical Analyst EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-05-06 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7721649003 EXCERPT: Associate Principal Statistical Analyst Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function. In addition to hands-on Programming, this position requires providing oversight and programming support and guidance for internal deliverables and regulatory submissions while ensuring conformance to CDISC standards and submission guidelines. Based on company needs, this position will be required to lead one or more early Phase or late phase studies/programs. Specific responsibilities include: - Effective collaborating with cross functional teams to provide programming timelines for various deliverables. - Provide SAS Programming technical support and guidance to programming team. - Oversight/participation in any internal/mock or regulatory authority audits. - Timeline and vendor management for deliverables, including submission-related activities, complying with regulatory standards (e.g., FDA 21 CFR Part 11, GxP). - Oversee the --- TITLE: Director, Target Biology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-04-23 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7712460003 EXCERPT: Director, Target Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Targets and Mechanisms group within Discovery Biology leverages expertise in cancer biology and deep mechanistic understanding of cancer-relevant pathways to identify and characterize high-priority oncology targets for our tri-complex inhibitor (TCI) platform. We are looking for an experienced drug hunter to lead the Target Biology team, provide hands-on scientific and people leadership, and work cross-functionally to identify and rapidly assess promising new targets, determine hit identification strategy, and advance screening hits through the early stages of hit-to-lead discovery. The ideal candidate will be a strategic thinker and an accomplished scientist with experience identifying and vetting targets for oncology programs, familiarity with different targeting modalities, including molecular glues, and hands-on hit to lead experience. In this role you will: - Lead a team of scientists focused on target identification, prioritization, and biological validation. - Work cross-functionally with partners in Medicinal Chemistry, Structural Biology, Discovery --- TITLE: Senior Specialist, Clinical Supply Chain EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $120K-$150K POSTED: 2026-05-14 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7732430003 EXCERPT: Senior Specialist, Clinical Supply Chain Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Independently support global clinical supply chain operations across multiple studies. This role is ideal for a detail-oriented, proactive professional who thrives in a fast-paced environment and can manage study-level supply planning, execution, and vendor coordination with minimal oversight. - Independently manage clinical supply chain activities for assigned studies, including planning, execution, and reconciliation. - Support global depot and site distribution, including coordination of Qualified Person (QP) release, import/export logistics, and temperature-controlled shipments. - Lead clinical label design, packaging, and labeling activities in collaboration with internal teams and external vendors. - Serve as the primary point of contact for CMOs, depots, and IRT vendors for assigned studies. - Develop and maintain study-level supply plans and forecasts, adjusting for protocol amendments, enrollment trends, and country/site activation. - Manage IRT system setup and maintenance, including drug assignment logic, inventory thresholds, and expiry management. - Monitor --- TITLE: Vice President, Healthcare Law EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $333K-$383K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695398003 EXCERPT: Vice President, Healthcare Law Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Vice President, Healthcare Law, reporting to the Deputy General Counsel, to join our RevMed team. The Vice President, Healthcare Law will provide strategic legal guidance related to the company's planned commercialization activities, including related to market access, patient access programs, distribution and licensing, and regulatory submissions. A successful candidate will bring proven experience working at a publicly traded life sciences organization, with demonstrated success in driving legal cross-functional strategy. - Serve as a legal advisor to members of the executive team on a wide range of commercialization issues with broad enterprise impact. - Serve as legal representative for Commercialization and Medical-related committees and teams, including promotional review, medical materials, and educational and charitable grants. - Serve as the lead counsel for healthcare regulatory law, including the FDCA and related Regulations, and Guidance Documents, fraud and abuse laws and guidances --- TITLE: Senior Director, Market Access, Spain EMPLOYER: Revolution Medicines LOCATION: Remote (Spain) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717864003 EXCERPT: Senior Director, Market Access, Spain Remote (Spain) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Market Access is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities. This position will partner with commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches. Responsibilities: - Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the Spain healthcare system. - HTA & Pricing Filings: Lead preparation and submission of value dossiers, --- TITLE: Clinical TMF Manager, Clinical Operations EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $143K-$178K POSTED: 2026-04-17 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7704686003 EXCERPT: Clinical TMF Manager, Clinical Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional. As a Clinical TMF and Systems Manager you will be responsible for acting as a central contact for the Clinical Study Execution Teams (CSETs) for Trial Master File (TMF) management and participating in the development of quality oversight processes for TMF management of RevMed's clinical trials. Additional responsibilities include the upload, review, and approval of TMF documents, co-authoring and managing TMF documents such as TMF Plan, Index, SOPs, and other guidance documents and ensuring quality management by reporting TMF metrics, periodic checks of adherence to SOPs, and reconciling all outstanding queries and issues (e.g., CAPAs). Support Clinical Operations Management in high-level projects, developing processes, strategies and conducting training for TMF stakeholders. Responsible for overseeing the activities of the TMF Specialist(s) and external vendors, ensuring that study documents are adherent with ICH-GCP guidelines, --- TITLE: Senior Director, Commercial, UK EMPLOYER: Revolution Medicines LOCATION: Remote (UK) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717844003 EXCERPT: Senior Director, Commercial, UK Remote (UK) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial, UK is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions. The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient- and physician relevant benefits). The Senior Director Commercial will further oversee the generation of insights from the therapeutic field, and translate these insights into a comprehensive, cross-functional strategy. Supporting a clear positioning and aligned communication approach, the incumbent will in addition secure the development and implementation of tactics and tools for the field force to effectively address customer needs. Responsibilities: - Act as the Commercial Lead --- TITLE: Principal Statistical Analyst EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-05-16 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7736313003 EXCERPT: Principal Statistical Analyst Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function. In addition to hands-on Programming, this position requires providing oversight and programming support and guidance for internal deliverables and regulatory submissions while ensuring conformance to CDISC standards and submission guidelines. Based on company needs, this position will be required to lead one or more early Phase or late phase studies/programs. Specific responsibilities include: - Effective collaborating with cross functional teams to provide programming timelines for various deliverables. - Provide SAS Programming technical support and guidance to programming team. - Oversight/participation in any internal/mock or regulatory authority audits. - Timeline and vendor management for deliverables, including submission-related activities, complying with regulatory standards (e.g., FDA 21 CFR Part 11, GxP). - Oversee the programming --- TITLE: Senior Director, Market Access, Italy EMPLOYER: Revolution Medicines LOCATION: Remote (Italy) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717868003 EXCERPT: Senior Director, Market Access, Italy Remote (Italy) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Market Access is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities. This position will partner with commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches. Responsibilities: - Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for oncology products within the Italian healthcare system. - HTA & Pricing Filings: Lead preparation and submission of value dossiers, --- TITLE: Senior Project Coordinator, Global Commercialization EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $106K-$132K POSTED: 2026-04-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7613767003 EXCERPT: Senior Project Coordinator, Global Commercialization Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Project Coordinator will be part of the Commercialization Effectiveness and Operations (CE&O) team. The role is essential to the execution and achievement of goals and objectives of the CE&O, Global Commercial Development and Global Market Access teams taking on accountability for project execution and logistical coordination across leadership and team members including: - Provides project planning and executional support for key events, activities and initiatives. Might need to travel for large events to ensure program components, materials, stakeholders, timelines and logistics are aligned for successful execution. - Leads meeting support, coordinates logistics, and partners with functional leaders in creation, preparation, organization and communication of key meeting materials for key meetings. - Serves as a coordination point across various stakeholders including leaders and team members at all levels, cross functional business partners and external vendors/ agencies. - Establishes processes, timelines and milestones to --- TITLE: Director, Global CMC Regulatory EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $211K-$264K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7693933003 EXCERPT: Director, Global CMC Regulatory Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global CMC Regulatory is a strategic leadership role responsible for developing, driving, and executing global commercial CMC regulatory strategies to secure and maintain marketing approvals for RevMed's product portfolio worldwide. This position provides leadership for commercial-stage CMC regulatory activities, including original marketing applications, global expansions, and post-approval lifecycle management. This role requires deep expertise in global commercial CMC regulatory frameworks, strong cross-functional leadership, and the ability to proactively anticipate regulatory risks while enabling business objectives. Responsibilities: - Develop and lead execution of effective global CMC regulatory strategies to support initial marketing approvals and lifecycle management of RevMed's product portfolio. - Oversee the preparation and submission of high-quality CMC dossiers for global marketing authorization applications and post-approval supplements/variations. Manage/lead interactions with Health Authorities as needed. - Assess the global regulatory implications of proposed CMC changes and provide proactive, risk-based guidance to optimize implementation and --- TITLE: Senior Director, Commercial, Spain EMPLOYER: Revolution Medicines LOCATION: Remote (Spain) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717831003 EXCERPT: Senior Director, Commercial, Spain Remote (Spain) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial, Spain is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions. The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient- and physician relevant benefits). The Senior Director Commercial will further oversee the generation of insights from the therapeutic field, and translate these insights into a comprehensive, cross-functional strategy. Supporting a clear positioning and aligned communication approach, the incumbent will in addition secure the development and implementation of tactics and tools for the field force to effectively address customer needs. Responsibilities: - Act as the Commercial Lead --- TITLE: Senior Manager, Analytical Development & QC EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695646003 EXCERPT: Senior Manager, Analytical Development & QC Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Playing a leading role and Subject Matter Expert (SME) of Quality Control within PDM Analytical Development & QC department in support of RevMed clinical and commercial programs, the position will be mainly responsible for managing QC activities from process validation to commercial manufacture of drug substance (DS), drug product (DP) and final product (FP), including managing stability programs, reference materials, and raw materials at contract organization. The candidate will also participate in post-approval QC related activities including lifecycle management regulatory submissions such as CBE, PAS, etc. - Provide support for stability program management, quality systems and QC documentation (e.g. SOPs) and PAI readiness and inspection as needed. - Coordinate and manage outsourced QC activities of late phase to commercial programs at CDMOs and / or contract testing labs (CTLs), including but not limited to in-process control test, final release test, and --- TITLE: Senior Manager, Workday Advanced Compensation EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-05-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7747172003 EXCERPT: Senior Manager, Workday Advanced Compensation Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As the Senior Manager, Workday Advanced Comp, you will serve as the functional lead for RevMed's Workday Advanced Compensation module, translating business needs into scalable, well-governed system solutions. You will combine deep configuration expertise with a strong consultative approach to enable scalable compensation programs, data integrity, compliance, and effective employee and manager experience. This role requires strong Workday Advanced Compensation expertise and broad Workday HCM systems knowledge. You will partner cross-functionally to drive optimization, governance, and continuous improvement across compensation processes while ensuring alignment with RevMed's mission and core values. You will report directly to the Director, People Operations & Systems. - Drive the Workday roadmap and continuous improvement strategy for Advanced Compensation and other Workday modules, prioritizing scalable, complaint solutions aligned with business objectives, operational efficiency, data integrity, and user experience. - Lead cross-functional initiatives and projects impacting compensation systems and --- TITLE: Director, Access Strategy Marketing NSCLC EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $211K-$264K POSTED: 2026-04-17 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7703635003 EXCERPT: Director, Access Strategy Marketing NSCLC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Access Strategy & Marketing will lead the development and execution of access strategy, value proposition development, and execution of marketing materials for the RevMed NSCLC portfolio (daraxonrasib, zoldonrasib and elironrasib). This role will focus on developing the short to medium term non-clinical value proposition across payers, HCPs, organized customers (GPOs, IDNs, etc) and channel partners. This role will be instrumental in supporting a successful launch through effective launch planning, tailored messaging to various customer types, and working cross-functionally with Market Access, Brand Marketing, Medical/HEOR, Regulatory and Compliance partners. The ideal candidate will also have experience in translating a dynamic policy and reimbursement landscape into access strategies over the product lifecycle (ie, impact of IRA, MFN, etc). This position is based out of our headquarters in Redwood City, CA. Remote candidates may be considered on case-by-case basis. Responsibilities may include: - Developing and --- TITLE: Director, GLP Quality Assurance EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-05-01 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7613313003 EXCERPT: Director, GLP Quality Assurance Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - The Director, Good Laboratory Practice Quality Assurance (GLP QA) is responsible for ensuring Good Laboratory Practices (GLP) compliance at RevMed and external vendors contracted to perform regulated work on behalf of RevMed including all GLP vendors. - Responsibilities include research laboratory vendors that perform work to support regulated clinical studies. - Develops the annual vendor audit plan. - The Director GLP QA performs and/or manages vendor audits including: - Development of the audit plan, audit conduct, and reporting - Tracking and coordination of audit closure tasks including review of observation responses from vendor(s) in conjunction with operational subject matter experts (SMEs), as applicable. - Provision of vendor approval recommendations - Maintenance of vendor approval status in Veeva. - Development and/or review of Quality Agreements - Performs or participates in internal audits. - Provides QA review of CRO study protocols and reports for --- TITLE: Associate Director, Business Operations EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-05-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7751588003 EXCERPT: Associate Director, Business Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Business Operations is an internal project manager with a consultant mindset and hands-on approach. This is an execution-focused role that strengthens the business capabilities in the Development & Clinical Sciences (DCS) organization. This role partners closely with the Development Leadership Team and the Program Leads to design and implement capabilities building projects that enable growth and evolve our ways of working. The role is ideal for a Associate Director -level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience. Responsibilities: - Enablement Programs & Tools - Design and deploy practical solutions (e.g., templates, toolkits, playbooks, workflows) that enable DCS teams in their day-to-day work. - Ensure solutions are practical, scalable, and embedded into existing processes. - Partner with subject-matter experts to translate complex --- TITLE: Senior Director, Global Patient Safety Science EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-20 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7515222003 EXCERPT: Senior Director, Global Patient Safety Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Global Patient Safety Science provides safety science and pharmacovigilance support to all products across the RevMed portfolio, which includes early and late phase development activities as a member of the Global Patient Safety team. The individual will be responsible for safety oversight and input into all aspects of study management across the portfolio. This position may have individual reporting to it depending on the program / portfolio being led. The Senior Director of Safety Science serves as the lead for multiple or large complex strategically important developmental programs. Works closely with the other functions as part of a flexible matrix team to conduct robust safety assessments and safety risk management activities. The Senior Director, Global Patient Safety Science will develop and maintain an expert understanding of the safety profile of the assigned product(s) as well as an understanding --- TITLE: Senior Director, Economic Modeling EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695564003 EXCERPT: Senior Director, Economic Modeling Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director of Economic Modeling is responsible for defining and executing the economic modeling strategy to produce high quality health economic models & modeling strategies across Rev Meds portfolio. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in Oncology. Key Strategic Responsibilities: - Lead the development of strategic and operational plans for health economic modeling within Global HEOR & RWE (e.g., early and submission cost-effectiveness / utility models, budget impact models, and country adaptations) while ensuring alignment with Integrated Evidence Plans and appropriate Global stakeholders. - Partner with Global HEOR & RWE Executive Directors on core health economic modeling plans to support HTA, payer, and other access stakeholder assessments, submissions, negotiations, including associated value/HTA deliverables and publications to meet business and access objectives. - Provide strategic, methodological --- TITLE: Senior Program Manager EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-06-03 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7762004003 EXCERPT: Senior Program Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is an exciting opportunity to advance first-in-Class RAS(ON) Inhibitors through clinical development. The ideal candidate is a strategic program management professional with deep experience leading cross-functional Companion Diagnostics (CDx) development activities supporting targeted oncology therapies. This individual will drive alignment across internal functions and external diagnostic partners to enable successful clinical development, regulatory execution, and commercialization readiness. The successful candidate will draw on their experience to: - Lead cross-functional Companion Diagnostics development programs supporting clinical-stage oncology assets from assay strategy through clinical and regulatory execution. - Work closely with CDx Leads and other clinical development team members to facilitate science-based CDx decision making and drive the execution of the CDx development strategy. - Develop and maintain integrated cross-functional program plans, timelines, milestones, dependencies, and critical path analyses across internal teams and external diagnostic partners. - Drive cross-functional alignment and coordinate CDx operational activities --- TITLE: Payroll Manager EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $143K-$178K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695380003 EXCERPT: Payroll Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Associate Director, Payroll, the Payroll Manager will be responsible for ensuring accurate, timely and compliant payroll processing from start to finish. This position is ideal for a payroll leader who thrives in fast-paced, ambiguous, and rapidly growing environments. The successful candidate will have deep experience in public company environments, understand stock compensation, and be well-versed in SOX compliance, audits, and employment tax. Responsibilities: - Manage full-cycle operations for the US payroll including but not limited to semi-monthly, equity, commission, off-cycle and bonus processing using ADP Workforce Now. - Support equity compensation processing including RSU, ISO, Non-Qual, and ESPP; ensuring accurate tax treatment and timely reporting. - Supervise and mentor a team of payroll professionals, providing leadership, development, and training. - Lead quarter-end and year-end payroll processes, including tax reporting, compliance filings and W-2/equivalent statement delivery. - Ensure compliance with local payroll, tax, --- TITLE: Regional Insights and Engagement Director, Lung, Southeast EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $231K-$254K POSTED: 2026-05-20 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7732649003 EXCERPT: Regional Insights and Engagement Director, Lung, Southeast Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Regional Insights and Engagement Director, Southeast is a field-based position focused on working closely with Lung Cancer Key Opinion Leaders (KOLs) at select institutions and accounts within the defined geography. This person is a RevMed clinical and product expert for Key Opinion Leaders and ensures that cross-functional resources are made available as appropriate. In this role, you will be a member of the commercial development team, and you will work closely with marketing, medical affairs, field sales, insights and analytics and other cross functional colleagues. You will help inform brand strategy, develop and execute KOL tactics and you will be evaluated in conjunction with individual performance and brand KPIs This role will cover major academic institutions, accounts, and the Lung Key Opinion Leaders located in the Southeast. Essential Duties: - Designs, executes, and implements significant national strategic marketing deliverables. --- TITLE: Senior Director, Regional Medical Science Liaison Team Lead - West EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $268K-$295K POSTED: 2026-04-17 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7703639003 EXCERPT: Senior Director, Regional Medical Science Liaison Team Lead - West Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Sr. Director will manage and coach a lung regional field medical team, oversee the regional field implementation plan and develop, deploy, and monitor key performance indicators and encourage individual professional development goals across the team. You will drive regional thought leader engagement strategy, foster scientific exchange, and lead insight generation strategies. Importantly, you will foster and identify opportunities to collaborate across functions and be instrumental in launch planning and execution. We are seeking a highly motivated and experienced leader to join our team as a Lung Regional Manager of Medical Science Liaisons. Key aspects of this front-line manager role will include: developing, mentoring, and coaching a team of MSL direct reports across approximately one half of the country. Required Skills, Experience and Education: - Collaborates with Field Medical Executive --- TITLE: Senior Director, Commercial, Italy EMPLOYER: Revolution Medicines LOCATION: Remote (Italy) (remote) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717842003 EXCERPT: Senior Director, Commercial, Italy Remote (Italy) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial, Italy is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions. The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient- and physician relevant benefits). The Senior Director Commercial will further oversee the generation of insights from the therapeutic field, and translate these insights into a comprehensive, cross-functional strategy. Supporting a clear positioning and aligned communication approach, the incumbent will in addition secure the development and implementation of tactics and tools for the field force to effectively address customer needs. Responsibilities: - Act as the Commercial Lead --- TITLE: Senior Machine Learning Scientist I, Drug Discovery Analytics EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $229K-$269K POSTED: 2026-03-24 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7677977003 EXCERPT: Senior Machine Learning Scientist I, Drug Discovery Analytics Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Senior Machine Learning Scientist to help accelerate drug discovery through advanced analytics and artificial intelligence. This role will develop predictive models and analytical methods that transform complex biological and chemical datasets into actionable insights that guide research decisions. The Senior Machine Learning Scientist will work at the interface of data science, chemistry, and biology to support target discovery, compound optimization, and translational research. This position requires both strong machine learning expertise and the ability to collaborate effectively with experimental scientists to solve real-world scientific problems. The successful candidate will contribute to building a data-driven discovery ecosystem where data, analytics, and experimentation continuously inform and accelerate one another. Key responsibilities include: - Develop Predictive Models for Drug Discovery. - Independently Design and implement machine learning models to predict compound activity, selectivity, and developability. - Identify and --- TITLE: Associate Director, Global Pricing Strategy & Analytics EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $177K-$221K POSTED: 2026-04-24 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7714049003 EXCERPT: Associate Director, Global Pricing Strategy & Analytics Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Pricing Strategy & Analytics will play a critical role in shaping and executing global pricing strategies across the portfolio. This individual will lead the development of pricing frameworks, provide advanced analytics, and generate insights to support value optimization and market access decisions. The role requires strong cross-functional collaboration with Market Access, Commercial, Finance, HEOR, and Regional teams to ensure pricing strategies are aligned with business objectives and external market dynamics. Key Responsibilities: Global Pricing Strategy - Support the development and execution of global pricing strategies for pipeline products across key markets. - Establish pricing guidance, guardrails, and launch sequencing strategies to optimize global value. - Evaluate pricing scenarios considering payer dynamics, competitive landscape, and regulatory constraints. - Support early asset strategy by integrating pricing considerations into clinical and commercial planning. Analytics & Insights - Design and deliver advanced --- TITLE: Associate Director, Global Regulatory Affairs Project Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695508003 EXCERPT: Associate Director, Global Regulatory Affairs Project Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Regulatory Affairs Project Management is an integral part of the global Regulatory Affairs organization and is responsible for translating global regulatory strategies into actionable execution plans. This role applies advanced project management expertise and operational leadership to guide cross-functional teams, supporting planned and ongoing drug marketing applications across RevMed programs. The role partners closely with Global Regulatory Science and Global Filing and Registration and contributes to the broader Global Regulatory Affairs function at RevMed. This position reports to the Senior Director, Global Regulatory Affairs Project Management. The ideal candidate will have an in-depth understanding of oncology drug development and demonstrated hands-on regulatory project management experience supporting early- and late-stage registrational programs, including the execution of global new drug marketing applications, in alignment with corporate objectives. Core Responsibilities: - Project manages regulatory submissions from initiation through submission, --- TITLE: Senior Director, Commercial, France EMPLOYER: Revolution Medicines LOCATION: Paris, France (unspecified) SALARY: Not disclosed POSTED: 2026-04-28 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7717816003 EXCERPT: Senior Director, Commercial, France Paris, France Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial, France is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions. The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient- and physician relevant benefits). The Senior Director Commercial will further oversee the generation of insights from the therapeutic field, and translate these insights into a comprehensive, cross-functional strategy. Supporting a clear positioning and aligned communication approach, the incumbent will in addition secure the development and implementation of tactics and tools for the field force to effectively address customer needs. Responsibilities: - Act as the Commercial Lead --- TITLE: Manager, FP&A, Europe EMPLOYER: Revolution Medicines LOCATION: Basel, Basel-Stadt, Switzerland (unspecified) SALARY: Not disclosed POSTED: 2026-06-04 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7763991003 EXCERPT: Manager, FP&A, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Manager, FP&A Europe will support the Sr Director FP&A Europe in driving financial planning, reporting, business analytics, and operational execution across the European region as the company prepares for commercial growth. Based in Basel, Switzerland, this role will coordinate budgeting and forecasting activities, deliver financial insights, support reporting and planning tools, and help ensure efficient day-to-day finance operations across European affiliates and functions. The ideal candidate is analytical, hands-on, highly organized, and comfortable operating in a fast-paced biotech environment. Support FP&A & Financial Operations - Support annual budget, quarterly forecast, and long-range planning processes across Europe. - Coordinate planning timelines, templates, and data collection with regional stakeholders. - Assist in maintaining European management P&L structures by country, function, and product. - Prepare monthly Actuals vs. Budget / Forecast reporting and variance analyses. - Consolidate and validate financial submissions from affiliates and functions. - Support OpEx --- TITLE: Executive Director, Cancer Immunology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-02-09 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7625384003 EXCERPT: Executive Director, Cancer Immunology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This role represents a unique opportunity to serve as a senior scientific and strategic leader within Cancer Immunology, with primary responsibility for driving the discovery and advancement of novel immuno-oncology targets and therapeutic modalities. We are seeking an accomplished leader who combines deep scientific expertise with strong people leadership to shape strategy, guide portfolio decisions, and advance high-impact discovery programs. The successful candidate will lead a multidisciplinary team to progress innovative immuno-oncology programs from early discovery through Development Candidate nomination, while providing senior oversight of scientific integration across Discovery and Translational Cancer Immunology. This role reports to the Vice President and Head of Cancer Immunology and partners closely with Research and Development leadership to support portfolio prioritization and governance. Key aspects of the role include: - Discovery Program Leadership & Protfolio Oversight : Provide executive-level leadership of Cancer Immunology discovery programs from project --- TITLE: Director, Global Forecasting EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $201K-$251K POSTED: 2026-04-29 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7515208003 EXCERPT: Director, Global Forecasting Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Sr. Director, Global Analytics and Insights, the Director, Global Forecasting role requires strategic thinking and expertise to provide critical contributions to disease area strategy, life-cycle planning and product and portfolio decisions. This role involves developing, refining, and communicating key strategic and revenue forecast assumptions and analyses to inform and support decision-making across the organization. This role will also work directly with Regional Forecasting leads to ensure consistency in forecast approach, assumptions, and analyses. The ideal candidate will have experience working on pipeline molecules in Oncology, strong problem-solving skills, a strategic mindset, and will exhibit curiosity, flexibility, and be comfortable with ambiguity. This position would ideally be based at our headquarters in Redwood City, CA., however open to remote candidates who are willing to travel to our CA office on a regular basis. Responsibilities include: - Develops and maintains long-term forecast models and --- TITLE: Safety Scientist EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $120K-$150K POSTED: 2026-06-09 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7767615003 EXCERPT: Safety Scientist Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Safety Scientist within Global Patient Safety Science is an individual contributor who provides safety science and pharmacovigilance support to all products across the RevMed portfolio, which includes early and late phase development activities. The individual will be responsible for supporting clinical studies, review of clinical trial protocols, supporting updates to IBs, ICFs, and authoring of DSURs. Additional safety related activities will involve medical review of individual case safety reports (ICSRs), safety surveillance of assigned products and active member of cross-functional teams. The Safety Scientist will develop and maintain an understanding of the safety profile of the assigned product(s). Responsibilities include: - Proactive medical safety surveillance of ongoing clinical trials for identification of safety - Conduct ongoing safety data reviews; prepare and present summaries to internal stakeholders. - Medical review of individual case safety reports and medical review of ICSRs, routine review of safety data --- TITLE: Senior Director, Compliance Training EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-05-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7613273003 EXCERPT: Senior Director, Compliance Training Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director of Compliance Training will lead the strategy, design, and execution of a global compliance training program for a biotechnology organization. This role is responsible for fostering a culture of ethics and compliance by delivering engaging, risk-based training aligned with regulatory requirements and industry best practices. The ideal candidate brings deep expertise in life sciences compliance, adult learning methodologies, and global training program management. This role will work closely with Learning & Development, Corporate Communications, Legal, HR, and business stakeholders to integrate compliance and legal training into broader enterprise learning, communications, and change-management efforts. - Develop and implement a comprehensive, risk-based compliance training strategy aligned with business objectives and regulatory expectations (e.g., FDA, OIG, DOJ, EMA). - Serve as a key advisor to the Vice President, Compliance and senior leadership on training-related compliance risks and mitigation strategies. - Continuously assess and --- TITLE: Associate Director, Global Commercialization Systems Enablement EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695502003 EXCERPT: Associate Director, Global Commercialization Systems Enablement Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Commercialization Systems Enablement is responsible for coordinating and enabling Commercial and Medical Affairs global systems work across markets outside the United States. This role ensures that regional needs are clearly understood, refined, and effectively integrated into established global processes, including launch orchestration, compliance frameworks, software development lifecycle practices, and prioritization governance. For new market launches outside of the United States, this individual will lead the associated Commercial and Medical business systems workstreams, ensuring coordinated planning, readiness, and execution across regional IT teams, global Commercial and Medical solution teams, and enterprise technology teams. The Associate Director adds value by clarifying requirements, identifying cross market commonalities, and reducing discovery work for global delivery teams such as Omnichannel Solutions, Data Solutions, Medical Affairs Solutions, and Field Solutions. The role supports seamless pull through of work into global intake and execution models, helping --- TITLE: Scientific Writer, Integrated Research Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $143K-$178K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695440003 EXCERPT: Scientific Writer, Integrated Research Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Scientific Writer with strong nonclinical regulatory experience to support the authoring and integration of nonclinical content for U.S. and global regulatory submissions. This role focuses on developing and integrating nonclinical content beyond INDs and NDAs, including briefing documents, Investigator Brochures, responses to health authority questions, and other submission-related materials across the U.S., Europe, and Asia. As a strategic scientific integrator, this individual will translate complex RAS biology and translational pharmacology into clear, compelling regulatory narratives that reflect RevMed's deep mechanistic understanding of RAS signaling and frontier targets. The role partners closely with nonclinical subject matter experts (SMEs) in pharmacology, toxicology, and DMPK, as well as Regulatory Affairs, Regulatory Operations, and Medical Writers, to ensure nonclinical strategy and content are scientifically rigorous, aligned, and submission-ready. The Scientific Writer will leverage structured source documents, document management systems, and emerging AI-enabled --- TITLE: Executive Director, Global Commercial Lead EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695206003 EXCERPT: Executive Director, Global Commercial Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. Candidates should be passionate about leading cross-functional collaboration, and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings. Specifically, you will be responsible for: - Partner across the company including with clinical development, medical affairs, market access, to drive indication strategy, shape brand strategies across the product team. - Ensure global readiness to drive successful launch planning, commercialization, and performance tracking across the U.S. and key ex-U.S. markets. - Execute global disease area strategy, brand strategies, including branding, --- TITLE: Senior Manager, Clinical Business Systems EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695658003 EXCERPT: Senior Manager, Clinical Business Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Clinical Systems is a hands-on technical leader responsible for the daily administration, support, and ongoing enhancement of core clinical systems, including eTMF and CTMS, as well as the implementation and optimization of future platforms that support clinical operations (e.g., RBQM, Study Start-Up, IRT/RTSM). This role will actively perform and oversee system configuration, user management, periodic reviews, and validation activities, ensuring systems remain compliant, reliable, and inspection ready. The individual will work closely with Clinical Operations, Data Management, Regulatory, CSV, Quality, and external vendors to support business needs while maintaining GxP compliance. Key responsibilities in this role include: - Act as the hands-on system owner/lead for assigned clinical systems, supporting daily operations and issue resolution. - Perform user lifecycle management activities including provisioning, modifications, deactivation, and role-based access control. - Execute and document periodic user access reviews and audit trail --- TITLE: Scientist II, Assay Operations, Screening Platform Technologies EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $132K-$166K POSTED: 2026-06-05 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7721647003 EXCERPT: Scientist II, Assay Operations, Screening Platform Technologies Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Scientist II, Assay Operations, Screening Platform Technologies (SPT) to support and scale next-generation cellular screening capabilities for oncology drug discovery. This role will focus on assay operations, screening execution, automation enablement, and assay scale-up to support high-throughput and high-content screening campaigns across early discovery and lead optimization programs. The successful candidate will partner closely with cross-functional collaborators across Discovery Sciences, Cancer Biology, Automation, Data Science, and external partners to establish robust, scalable, and operationally efficient screening workflows. This position is ideal for a scientist with strong experience executing and operationalizing cellular assays who enjoys working at the intersection of biology, automation, and screening infrastructure. In this role, you will support the transfer, optimization, execution, and scaling of cellular assays across multiple screening platforms, helping ensure assays are automation-ready, reproducible, and fit for high-throughput applications. You will --- TITLE: Lab Automation Engineer EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $99K-$124K POSTED: 2026-05-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7729946003 EXCERPT: Lab Automation Engineer Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an Associate Automation Engineer to join our laboratory automation team. The successful candidate will support the day-to-day operation, maintenance, troubleshooting, and optimization of automated laboratory instrumentation and integrated automation systems. This individual will work closely with scientists, engineers, and cross-functional teams to ensure reliable laboratory operations and support automation-driven workflows. The ideal candidate will have hands-on experience with laboratory automation platforms, instrumentation support, software-driven workflows, equipment validation, and troubleshooting of mechanical systems, along with a strong interest in process improvement and operational efficiency. As a member of the Automation Engineering team, you will contribute to the team with accountability for the following: - Develop and maintain automation methods using laboratory control platforms such as Tecan FluentControl, Hamilton Venus, Agilent VWorks, HighRes Cellario Scheduler, and Beckman Coulter Tempo/Echo. - Provide hands-on support, troubleshooting, and maintenance for automated laboratory instrumentation and integrated automation --- TITLE: Associate Director, Integrated Research Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695514003 EXCERPT: Associate Director, Integrated Research Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Integrated Research Management provides leadership across Research disciplines to strengthen operational execution, organizational clarity, and cross-functional alignment within the Discovery organization. This role translates Research strategy into actionable discipline-level plans and drives operational effectiveness within and across scientific teams. The Associate Director partners with Research leadership to identify business and scientific challenges, improve operating frameworks, and implement scalable solutions that support Discovery performance and organizational growth. - Translate Research strategy into clear operating plans and drive disciplined execution across Discovery workflows. - Establish and enforce operational objectives, processes, and decision frameworks that improve cross-disciplinary coordination and execution performance. - Diagnose and resolve complex operational challenges, removing friction and strengthening clarity, speed, and accountability in program advancement. - Lead and implement change initiatives within Research, ensuring stakeholder alignment and sustained adoption of improved processes and digital tools. - Partner directly --- TITLE: Director, Global Regulatory Affairs Project Management EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-04-22 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7710393003 EXCERPT: Director, Global Regulatory Affairs Project Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Regulatory Affairs Project Management is an integral part of the global Regulatory Affairs organization and is responsible for translating global regulatory strategies into actionable execution plans. This role applies advanced project management expertise and operational leadership to guide cross-functional teams, supporting planned and ongoing drug marketing applications across RevMed programs. The role partners closely with Global Regulatory Science and Global Filing and Registration and contributes to the broader Global Regulatory Affairs function at RevMed. This position reports to the Senior Director, Global Regulatory Affairs Project Management. The ideal candidate will have an in-depth understanding of oncology drug development and demonstrated hands-on regulatory project management experience supporting early- and late-stage registrational programs, including the execution of global new drug marketing applications, in alignment with corporate objectives. Core Responsibilities: - Project manage regulatory submissions from initiation through submission, supporting the --- TITLE: Executive Director, Computational Systems Biology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7694323003 EXCERPT: Executive Director, Computational Systems Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As an Executive Director and Head of Research Computational Biology within our Biology Function, the individual will oversee the scientific and strategic direction of systems biology research and preclinical computational biology initiatives. The individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. We are looking for an experienced leader with strong interpersonal skills and an ability to lead a strong and diverse computational biology team. Key aspects of the role include: - Strategic vision and leadership: Develop and implement a long-term strategy for research systems biology and bioinformatic activities to support a growing pipeline of RAS(ON) and novel targeted inhibitors. Lead and supervise --- TITLE: Executive Director, Analytics & Insights (NSCLC) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-04-21 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7709044003 EXCERPT: Executive Director, Analytics & Insights (NSCLC) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Vice President, US Analytics & Insights, this role will serve as the analytics and insights leader dedicated to the Lung franchise, supporting launch planning and commercialization readiness for lung cancer assets. This individual will play a critical role in shaping franchise strategy through data-driven insights, while closely collaborating with forecasting, commercial, medical, and market access partners. This leader will operate as a player/coach, balancing hands-on analytical leadership with team development, and will be expected to personally contribute to high-priority strategic analyses while building and scaling a high-performing team. Candidates should bring deep oncology expertise, strong leadership capabilities, and a track record of translating complex data into actionable business insights within a fast-growing organization. This position is based out of our headquarters in Redwood City, CA. Responsibilities include: - Serve as the franchise lead for Analytics & Insights --- TITLE: Regional Insights and Engagement Director, Lung, Central Rockies EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $231K-$254K POSTED: 2026-05-19 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7732651003 EXCERPT: Regional Insights and Engagement Director, Lung, Central Rockies Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Regional Insights and Engagement Director, Central Rockies is a field-based position focused on working closely with Lung Cancer Key Opinion Leaders (KOLs) at select institutions and accounts within the defined geography. This person is a RevMed clinical and product expert for Key Opinion Leaders and ensures that cross-functional resources are made available as appropriate. In this role, you will be a member of the commercial development team, and you will work closely with marketing, medical affairs, field sales, insights and analytics and other cross functional colleagues. You will help inform brand strategy, develop and execute KOL tactics and you will be evaluated in conjunction with individual performance and brand KPIs. This role will cover major academic institutions, accounts, and the Lung Key Opinion Leaders located in the Central Rockies. Essential Duties: - Designs, executes, and implements significant national --- TITLE: Associate Director, Statistical Programming EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-05-12 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7731519003 EXCERPT: Associate Director, Statistical Programming Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function. In addition to hands-on Programming, this position requires providing oversight and programming support and guidance for internal deliverables and regulatory submissions while ensuring conformance to CDISC standards and submission guidelines. Based on company needs, this position will be required to lead one or more early Phase or late phase studies/programs. Specific responsibilities include: - Effective collaborating with cross functional teams to provide programming timelines for various deliverables. - Provide SAS Programming technical support and guidance to programming team. - Oversight/participation in any internal/mock or regulatory authority audits. - Timeline and vendor management for deliverables, including submission-related activities, complying with regulatory standards (e.g., FDA 21 CFR Part 11, GxP). - Oversee the --- TITLE: Senior Director, Global Medical Affairs - GI Oncology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-05-13 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7648531003 EXCERPT: Senior Director, Global Medical Affairs - GI Oncology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the GI Tumors Medical Affairs Strategy Lead, the Senior Director, Global Medical Affairs, will be responsible for developing and executing the Global Medical Affairs (GMA) strategy and tactical plans with a focus on launch readiness, launch implementation and life cycle management for an individual asset. The successful candidate will have a proven track record of developing and driving medical strategies with a focus on effectively communicating key scientific data through publications, medical information, medical communications, and congress activities. The successful candidate will also have experience gathering and analyzing insights through Advisory Boards, Key Opinion Leader (KOL) engagements and interaction with local/regional medical teams and translating those insights into tactics that optimize asset utilization and impact the drug lifecycle. This role requires close collaboration with cross-functional counterparts across Development, Research and Commercial as well as other internal partners, --- TITLE: Senior Director, Regional Medical Science Liaison Team Lead - East EMPLOYER: Revolution Medicines LOCATION: Remote (United States) (remote) SALARY: $268K-$295K POSTED: 2026-04-17 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7703637003 EXCERPT: Senior Director, Regional Medical Science Liaison Team Lead - East Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Sr. Director will manage and coach a lung regional field medical team, oversee the regional field implementation plan and develop, deploy, and monitor key performance indicators and encourage individual professional development goals across the team. You will drive regional thought leader engagement strategy, foster scientific exchange, and lead insight generation strategies. Importantly, you will foster and identify opportunities to collaborate across functions and be instrumental in launch planning and execution. We are seeking a highly motivated and experienced leader to join our team as a Lung Regional Manager of Medical Science Liaisons. Key aspects of this front-line manager role will include: developing, mentoring, and coaching a team of MSL direct reports across approximately one half of the country. Required Skills, Experience and Education: - Collaborates with Field Medical Executive --- TITLE: Senior Director, Global Commercial Development EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695570003 EXCERPT: Senior Director, Global Commercial Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team. Candidates should be passionate about leading cross-functional collaboration and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings. Specifically, you will be responsible for: - Partner across the company including with clinical development, medical affairs, market access, to drive indication strategy, shape brand strategies across the product team. - Ensure global readiness to drive successful launch planning, commercialization, and performance tracking across the U.S. and key ex-U.S. markets. - Execute global disease area strategy, brand strategies, including branding, positioning, messaging, and value propositions that guide regional affiliates and align with --- TITLE: Director, Forecasting (Lung) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-04-23 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7712462003 EXCERPT: Director, Forecasting (Lung) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Senior Director, U.S. Forecasting, the Director, U.S. Forecasting will be responsible for developing and executing forecasting models and analyses that support product strategy, performance management, and operational planning. This role focuses on building and maintaining short-term demand forecasts and patient-based models across U.S. oncology assets, enabling manufacturing, supply chain, and commercial decision-making. The Director will partner closely with cross-functional stakeholders to align on forecast inputs, assumptions, and outputs, while ensuring high-quality, timely deliverables. As a key contributor within the U.S. Forecasting function, this individual will execute forecasting processes in alignment with the broader U.S. forecasting strategy and contribute to ongoing improvements in forecasting capabilities, tools, and data integration. This position is based at our Redwood City, CA headquarters, with flexibility for remote candidates willing to travel regularly to the office. Responsibilities include: - Develop, maintain, and refine short-term demand forecasts across --- TITLE: Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $265K-$331K POSTED: 2026-05-05 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7515216003 EXCERPT: Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director of GCP QA is a senior leadership role responsible for setting and executing the global GCP quality strategy across clinical development programs. This position ensures compliance with regulatory requirements, industry standards, and company policies governing clinical trials. The role provides strategic oversight of GCP QA activities, including leadership of a high-performing QA team, governance of contract research organizations, and advancement of continuous improvement initiatives to uphold the highest standards of quality and patient safety. Serving as the GCP QA lead for late-stage clinical programs, this individual is accountable for GCP, GLP, and Pharmacovigilance/Safety oversight across multiple RevMed studies and represents QA in cross-functional and executive forums. The Executive Director will serve as a key advisor to senior leadership on clinical quality risk and regulatory readiness, helping to shape development strategy and enable successful regulatory outcomes. --- TITLE: Scientist II, Structural Biology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $132K-$166K POSTED: 2026-05-01 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7721467003 EXCERPT: Scientist II, Structural Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are looking for motivated structural biologist to join tour team to support multiple oncology therapeutic programs. The ideal candidate will have previous, hands-on experience in sample preparation, data acquisition and data analysis from both X-ray crystallography and cryo-EM. They will apply their expertise to form compound driven complexes, identify, and optimize crystallization/CryoEM conditions with the aim of determining high resolution structural information to drive small molecule design and mechanistic understanding. We're seeking a team player with enthusiasm to work in an interdisciplinary setting to drive toward new, cutting edge oncology therapeutics. Responsibilities - Plan and execute experiments with the aim of determining small molecule driven multi-protein complex structures by CryoEM and X-ray crystallography. - Perform cryo-EM grid screening, optimization, data collection and refinement to enable high-quality structure determination. - Interact with interdisciplinary teams (including chemists, computational chemists, biologists, project teams, and management) --- TITLE: ERP Systems Senior Manager (NetSuite) EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695632003 EXCERPT: ERP Systems Senior Manager (NetSuite) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a ERP Systems Senior Manager to serve as the primary owner and hands-on lead for NetSuite OneWorld, supporting our growing global operations and commercialization readiness. This is an individual contributor role responsible for both day-to-day system execution and longer-term ERP design and scalability. You will partner closely with Finance, FP&A, Accounting, Tax, Procurement, and IT to ensure NetSuite is accurate, compliant, scalable, and tightly aligned with business processes. This role combines deep hands-on system configuration and support with the ability to design and continuously improve ERP capabilities as the organization grows. You will play a critical role in maintaining financial integrity, supporting global entity expansion, optimizing inventory and product costing, and ensuring seamless integration across enterprise systems including Workday, Coupa, Concur, ADP, and middleware platforms. This role is pivotal in building sustainable, audit-ready ERP operations to support scale and --- TITLE: Senior Clinical Program Manager, Clinical Operations EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $164K-$205K POSTED: 2026-05-20 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7741066003 EXCERPT: Senior Clinical Program Manager, Clinical Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. - Conduct risk management, contingency, and scenario planning. - Supervise, communicate project status/issues, and problem solve to ensure project team goals are met. - Participate in the development of all study-related documentation, including study protocols. - Actively contribute in the selection and management of --- TITLE: Senior Product Manager, Biology EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $186K-$233K POSTED: 2026-05-19 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7738667003 EXCERPT: Senior Product Manager, Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Senior Product Manager, Biology to shape products and capabilities that help Biology and Discovery teams design, execute, analyze, and learn from experiments faster, with trusted data and AI-enabled support. This role will define and deliver product strategy for Biology workflows, data products, and AI-enabled decision support on RevCore, our enterprise Data, Digital, and AI platform. The mandate is to improve experiment traceability, reduce manual data preparation, accelerate cross-study analysis, and make Biology insights easier to generate and act on. You will partner with scientists across Protein Science, Structural Biology, Screening Sciences, Sample Management, In Vivo Research, Pathology, Translational Research, Computational Biology, Data Science, ML Engineering, Data Engineering, IT, and platform teams to turn complex research workflows into intuitive, scalable products. Product surfaces may include experiment planning workflows, assay and screening result review, sample and reagent lineage, cross-study analysis, and --- TITLE: Senior Accountant, General Ledger, Europe EMPLOYER: Revolution Medicines LOCATION: Basel, Basel-Stadt, Switzerland (unspecified) SALARY: Not disclosed POSTED: 2026-06-04 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7763961003 EXCERPT: Senior Accountant, General Ledger, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated individual with a background in the life sciences industry to play a critical role in the accounting team. Reporting directly to the Senior Director, Accounting Europe, this newly created role will support the daily accounting operations operations across multiple European entities. This role will be responsible for maintaining accurate financial records, supporting month-end and year-end US GAAP and local GAAP close activities, preparing journal entries and reconciliations, VAT reporting, and ensuring compliance with company policies, internal controls, and applicable accounting standards. The role is located in Basel, Switzerland. - Perform day-to-day general ledger accounting activities for European entities. - Prepare journal entries such as cash, prepayments, accruals, fixed assets, leases and other month-end close adjustments. - Support monthly, quarterly, and annual close processes in accordance with company timelines. - Prepare balance sheet reconciliations and investigate variances in a timely --- TITLE: Director, Human Resources Technology – Workday Architect EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $211K-$264K POSTED: 2026-05-27 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7648497003 EXCERPT: Director, Human Resources Technology – Workday Architect Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a rapidly growing biotech company, we are scaling our enterprise systems to support a dynamic workforce, evolving regulatory requirements, and complex financial operations. We are seeking a Workday Architect person to lead the design, development, and optimization of our Workday platform. - Oversee the end-to-end architecture, governance, and optimization of the Workday ecosystem including HCM, Learning, Talent, Peakon, Sana, and Advanced Compensation etc. - Provide architectural oversight and governance for external implementation partners, AMS providers, and integration vendors to ensure alignment with enterprise standards and strategic objectives. - Drive enterprise architecture decisions across the HR technology ecosystem by partnering with IT Enterprise Architecture, IT Security, and Finance teams to ensure scalable, compliant, and business-aligned solutions across Workday and interconnected enterprise platforms. - Lead adoption and governance of AI-enabled HR technologies, intelligent automation, and digital workflow capabilities across the Workday --- TITLE: Senior Director, Global CMC Lead EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-05-21 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7746551003 EXCERPT: Senior Director, Global CMC Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic, collaborative, and execution-oriented leader for the role of Senior Director, Global CMC Lead. The Senior Director, Global CMC Lead will provide cross-functional leadership and accountability for defining and executing integrated CMC strategies across development-stage and late-stage small molecule programs. This individual will partner closely with CMC cross functional teams, Regulatory, Quality, Clinical Development, and external partners to advance programs efficiently from development through commercialization readiness. The ideal candidate will bring deep expertise in small molecule pharmaceutical development and manufacturing, a strong understanding of the oncology drug development lifecycle, and the ability to thrive in a dynamic, fast-paced, and highly collaborative environment. Responsibilities: - Lead and execute integrated global CMC strategies across assigned development programs from early development through commercialization readiness. - Serve as the primary CMC lead on cross-functional program teams, accountable for CMC timelines, deliverables, risks, --- TITLE: Senior Director, Head of Early Development Regulatory Affairs EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: $244K-$305K POSTED: 2026-04-10 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7695578003 EXCERPT: Senior Director, Head of Early Development Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Head of Early Development Regulatory Affairs will lead global regulatory strategy for early-stage programs (pre-IND through Phase 2) across the portfolio. This leader will shape innovative and efficient regulatory pathways that enable rapid, science-driven development while positioning assets for long-term success. In addition to strategic leadership, this role will build and scale fit-for-purpose regulatory processes, frameworks, and capabilities to support portfolio growth. The position reports to the Head of Regulatory Sciences and serves as a key member of the Regulatory leadership team. Primary Responsibilities: Early Development Strategy - Lead global regulatory strategy from candidate selection through end-of-Phase 2. - Shape early clinical development strategy by providing regulatory leadership on dose-finding approaches and indication selection that enable accelerated and differentiated development pathways and position asset for global registration and Health Authority Engagement. - Oversee strategy and cross --- TITLE: Staff Cloud Infrastructure, Scientific Computer Engineer EMPLOYER: Revolution Medicines LOCATION: Redwood City, California, United States (unspecified) SALARY: Not disclosed POSTED: 2026-05-19 K401_MATCH: yes (not source-backed) APPLY_URL: https://www.revmed.com/careers-list/?gh_jid=7721641003 EXCERPT: Staff Cloud Infrastructure, Scientific Computer Engineer Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Staff Cloud Infrastructure, Scientific Computer Engineer to help build, operate, and improve the infrastructure foundations that support computational science, data engineering, analytics, and enterprise business operations across RevMed. This role will partner with scientific, G&A, data, security, and IT stakeholders to deliver reliable, secure, scalable compute and platform services. The ideal candidate brings deep infrastructure experience, strong operational judgment, and the ability to translate scientific and business computing needs into practical, reusable platform patterns. What You'll Do: - Design, operate, and improve secure cloud infrastructure for R&D and scientific computing workloads. - Build reusable infrastructure patterns for compute, storage, networking, identity, secrets management, and observability. - Use Infrastructure as Code, primarily Terraform, to standardize provisioning and change management. - Support high-throughput and scientific compute environments, including HPC and scheduler-based workloads. - Enable reproducible compute patterns using Linux, --- TITLE: Pharmacovigilance Scientist EMPLOYER: Tonix Pharmaceuticals Holding Corp LOCATION: Berkeley Heights, NJ (unspecified) SALARY: $124K-$170K POSTED: 2026-04-02 K401_MATCH: yes (not source-backed) APPLY_URL: https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4205666009 EXCERPT: Pharmacovigilance Scientist Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking an experienced Pharmacovigilance Scientist --- TITLE: Scientist II, Animal Model Development EMPLOYER: Tonix Pharmaceuticals Holding Corp LOCATION: Frederick, MD (unspecified) SALARY: $70K-$120K POSTED: 2026-03-05 K401_MATCH: yes (not source-backed) APPLY_URL: https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4170744009 EXCERPT: Scientist II, Animal Model Development Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix Research and Development Center --- TITLE: TECHNICAL SUPPORT - BOSS REVOLUTION EMPLOYER: IDT CORP LOCATION: Guatemala City (unspecified) SALARY: Not disclosed POSTED: 2026-06-04 K401_MATCH: yes (not source-backed) APPLY_URL: https://jobs.lever.co/idt/a7df18e1-ec54-44b5-8835-9e3dc854407d EXCERPT: TECHNICAL SUPPORT - BOSS REVOLUTION Guatemala City --- TITLE: CORE Engineer EMPLOYER: Corning LOCATION: Reynosa (unspecified) SALARY: Not disclosed POSTED: 2026-06-12 PARENTAL_LEAVE_WEEKS: 12 (not source-backed) NON_BIRTH_PARENT_LEAVE_WEEKS: 12 (not source-backed) K401_MATCH: yes (not source-backed) APPLY_URL: https://corningjobs.corning.com/job/Reynosa-CORE-Engineer-TAM-88730/1377425500/ EXCERPT: CORE Engineer Reynosa Requisition Number: 73989 The company built on breakthroughs. ​ Join us.​ Corning is one of the world's leading innovators in glass, ceramic, and materials science. From the depths of the ocean to the farthest reaches of space, our technologies push the boundaries of what's possible. ​ How do we do this? With our people. They break through limitations and expectations - not once in a career, but every day. They help move our company, and the world, forward. ​ ​At Corning, there are endless possibilities for making an impact. You can help connect the unconnected, drive the future of automobiles, transform at-home entertainment, and ensure the delivery of lifesaving medicines. And so much more.​ ​Come break through with us. Our Optical Communications segment has recently evolved from being a manufacturer of optical fiber and cable, hardware and equipment to being a comprehensive provider of industry-leading optical solutions across the broader communications industry.This segment is classified into two main product groupings - carrier network and enterprise network. The carrier network product group consists primarily of products and solutions for optical-based communications infrastructure for services such as video, data and voice communications. The enterprise network product group consists primarily of optical-based communication networks sold to businesses, governments and individuals for their own use. Role Purpose Why You Matter: Are you ready to join the revolution? Thr --- TITLE: Postdoctoral Fellowship-Immunology EMPLOYER: Tonix Pharmaceuticals Holding Corp LOCATION: Frederick, MD 21701 (unspecified) SALARY: $75K-$95K POSTED: 2026-05-18 K401_MATCH: yes (not source-backed) APPLY_URL: https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4245264009 EXCERPT: Postdoctoral Fellowship-Immunology Frederick, MD 21701 Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking a highly motivated and --- TITLE: Director, Precision Medicine (Cell Medicine) EMPLOYER: Regeneron Pharmaceuticals LOCATION: 2 Locations (unspecified) SALARY: Not disclosed POSTED: 2026-06-08 PARENTAL_LEAVE_WEEKS: 12 (not source-backed) NON_BIRTH_PARENT_LEAVE_WEEKS: 12 (not source-backed) K401_MATCH: yes (not source-backed) APPLY_URL: https://regeneron.wd1.myworkdayjobs.com/Careers/job/Cambridge/Director--Precision-Medicine_R46672-1 EXCERPT: Director, Precision Medicine (Cell Medicine) 2 Locations posted: Posted 4 Days Ago --- [PASTE YOUR RESUME OR SKILLS HERE]